03 September 2018
A report by visiongain, published in August 2016, predicts overall global sales of companion diagnostic products will reach $10.52 billion in 2020. That sales expansion will continue strongly through to 2026, helped by the entrance of new industry players, advances in diagnostic technology and developments in personalised medicine.
That revenue forecast and other analyses appear in Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016 – Market Analysis and Company Profiles Including Abbott Laboratories, Myriad Genetics, Roche, Qiagen, Agilent Technologies, Siemens, Johnson & Johnson and Other Companies in the US, Europe, Israel, India, Canada and South Korea, Exploring those Diagnostic Products for Personalised Medicine and Partnerships with Pharmaceutical Developers.
Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial prospects of industries and markets in healthcare and other fields.
Companion diagnostics are in vitro diagnostic tests providing information for the safe and effective use of corresponding drugs. The use of those tests helps physicians evaluate the efficacy and safety of a specific pharmaceutical in a group or sub-group of patients. Certain drugs have been known to be effective only in sub-segments of the patient population. The use of companion diagnostics allows for therapies to be administered only to people who are most likely to benefit from a particular treatment, aiding therapeutic efficiency and cost effectiveness.
Visiongain's new survey analyses 17 leading companion diagnostic developers, manufacturers and marketers from the US, Europe, Asia-Pacific and Israel, including these companies:
• Abbott Laboratories
• Myriad Genetics
• Genomic Health
• Thermo Fisher Scientific
• Johnson & Johnson
• Siemens Healthcare.
That investigation discusses top companies, exploring their activities by:
• Analysing companion diagnostic product portfolios and technologies
• Investigating the status of commercial developments
• Assessing R&D and products’ applications
• Uncovering organisations’ strengths, weaknesses, activities, strategies and prospects
• Giving qualitative analyses and revenue forecasting of the companion diagnostics market, explaining opportunities and challenges from 2016.
Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostic tests and outsourced services.
Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.
15 June 2021
Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.
14 June 2021
Rising preference for personalised medicine in developed as well as developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase NGS market concentration over the forecast period.
04 June 2021
The rising frequency of bacterial and viral diseases coupled with increased focus on immunisation programmes are two main reasons that are expected to boost the global anti-infective vaccines market’s growth in the coming years.